Cover page for clin icaltrials. gov 
 
 
Protocol title:   Improving How People Living with Dementia Are Selected for Care Coordination:  A Pragmatic Clinical Trial Embedded in an Accountable 
Care Organization  
 
NCT number:   [STUDY_ID_REMOVED] 
 
Protoc ol date:    November 2, 2023  
 
 
Protocol Template, Version 3.0 i  Clinical Interventional Study  
Protocol Template  
  
Protocol Template, Version 3.0 ii  PREFACE  
The Clinical Intervention Study Protocol Template is  a suggested format  for clinical trials 
sponsored by the National Institute on Aging (NIA) . Investigators are encouraged to use this 
format, as appropriate, when developing protocols for their studies. Large multi -site 
observational studies will also benefit from this protocol template.  
Note that instructions and explanatory text are indicated by italics and should be replaced in 
your protocol with appropriate text.  Section headings and template text formatted in regular 
type should be included in your protocol document as provided in the template.  
The goal of this template is to  provide a general format applicable to all  single - and multicenter  
clinical intervention trials (e.g., drug, surgery, behavioral, nutritional, device, etc).  
As you can see the version number and date are on the bottom of each page. When making changes to an approved and ‚Äúfinal‚Äù protocol, please provide a summary of the changes, with the date, at the front of the protocol. 
List of changes to the protocol  
 
Protocol number  Date of Protocol  Revision made, if any  
1 May 11, 2022 Original approved protocol  
2 September 9, 2022  Adding an exclusion for people enrolled in home 
hospice  
3 October 26, 2022  Stratifying randomization by care management team  
4 November 2, 2023  Changing 24- hour reporting requirement from all 
deaths to unexpected deaths  and updating reporting 
logistics  
 
  
Protocol Template, Version 3.0 iii   
FULL PROTOCOL TITLE  
 
Improving How People Living with Dementia Are Selected for Care Coordination:  
A Pragmatic Clinical Trial Embedded in an Accountable Care Organization  
 
Study Chairman or Principal Investigator:  
 
Lisa M. Kern, MD, MPH, Associate Professor of Medicine, Weill Cornell Medicine  
 
 
Supported by : 
The National Institute on Aging  
 NIA IMPACT Collaboratory  
FY22_Demo2_Kern  
Study Intervention Provided by:  
Not applicable  
Sponsor of IND /IDE:   
Not applicable  
(Any modification to the protocol should be annotated on the coversheet or in an appendix.  The 
annotation should note the exact words that are changed, the location in the protocol, the date 
the modification was approved, and the date it became effective .)  
Version 4  
November 2, 2023
Protocol Template, Version 3.0 iv TABLE OF CONTENTS  
Page 
PREFACE  ...................................................................................................................................... ii 
FULL PROTOCOL TITLE  ........................................................................................................ iii 
TABLE OF CONTENTS  ............................................................................................................ iv 
PR√âCIS  ........................................................................................................................................ vii 
Study Title  ................................................................................................................................. vii  
Objectives  ................................................................................................................................. vii  
Design and Outcomes ............................................................................................................... vii  
Interventions and Duration ...................................................................................................... viii 
Sample Size and Population..................................................................................................... viii 
STUDY TEAM ROSTER............................................................................................................. 1  
Principal Investigator:  ........................................................................................................................... 1 
Co-Investigators:  .................................................................................................................................... 1 
PARTICIPATING STUDY SITES  ............................................................................................. 2  
1 Study objectives  ..................................................................................................................... 3  
1.1 Primary Objective  ........................................................................................................... 3  
1.2 Secondary Objectives ...................................................................................................... 3  
2 BACKGROUND AND RATIONALE  ................................................................................ 3  
2.1 Background on Condition, Disease, or Other Primary Study Focus .............................. 3  
2.2 Study Rationale ............................................................................................................... 4  
3 STUDY DESIGN  ................................................................................................................... 5  
4 SELECTION AND ENROLLMENT OF PARTICIPANTS  ............................................ 6  
4.1 Inclusion Criteria  ............................................................................................................ 6  
4.2 Exclusion Criteria  ........................................................................................................... 7  
4.3 Study Enrollment Procedures ......................................................................................... 7  
5 STUDY INTERVENTIONS  .............................................................................................. 10  
Protocol Template, Version 3.0 v 5.1 Interventions, Administration, and Duration  ................................................................ 10 
5.2 Handling of Study Interventions  ................................................................................... 10 
5.3 Concomitant Interventions  ............................................................................................ 12 
5.3.1  Allowed Interventions  ............................................................................................... 12 
5.3.2  Required Interventions  .............................................................................................. 12 
5.3.3  Prohibited Interventions  ............................................................................................ 12 
5.4 Adherence Assessment  ................................................................................................. 12 
6 STUDY PROCEDURES  .................................................................................................... 12 
6.1 Schedule of Evaluations  ................................................................................................ 12 
6.2 Description of Evaluations  ............................................................................................ 13 
6.2.1  Screening Evaluation  ................................................................................................ 13 
6.2.2  Enrollment, Baseline, and/or Randomization ........................................................... 14 
6.2.3  Follow -up Visits ........................................................................................................ 14 
6.2.4  Completion/Final Evaluation  .................................................................................... 14 
7 SAFETY ASSESSMENTS  ................................................................................................. 14 
7.1 Specification of Safety Parameters  ............................................................................... 14 
7.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters  .... 14 
7.3 Adverse Events and Serious Adverse Events  ............................................................... 14 
7.3.1  Reporting Procedures  ................................................................................................ 15 
7.3.2  Follow -up for Adverse Events  .................................................................................. 16 
7.4 Safety Monitoring ......................................................................................................... 17 
8 INTERVENTION DISCONTINUATION........................................................................ 17 
9 STATISTICAL CONSIDERATIONS  .............................................................................. 17 
9.1 General Design Issues  ................................................................................................... 17 
9.2 Sample Size and Randomization  .................................................................................. 18 
9.2.1  Treatment Assignment Procedures  ........................................................................... 18 
9.3 Interim analyses and Stopping Rules  ............................................................................ 19 
9.4 Outcomes  ...................................................................................................................... 19 
9.4.1  Primary outcome  ....................................................................................................... 19 
9.4.2  Secondary outcomes  ................................................................................................. 19 
9.5 Data Analyses  ............................................................................................................... 19 
10 DATA COLLECTION AND QUALITY ASSURANCE  ................................................ 20 
10.1  Data Collection Forms  .................................................................................................. 20 
Protocol Template, Version 3.0 vi 10.2  Data Management  ......................................................................................................... 20 
10.3  Quality Assurance  ......................................................................................................... 20 
10.3.1  Training ................................................................................................................. 20 
10.3.2  Quality Control Committee ................................................................................... 20 
10.3.3  Metrics  .................................................................................................................. 20 
10.3.4  Protocol Deviations  ............................................................................................... 21 
10.3.5  Monitoring ............................................................................................................ 21 
11 PARTICIPANT RIGHTS AND CONFIDENTIALITY ................................................. 21 
11.1  Institutional Review Board (IRB) Review  .................................................................... 21 
11.2  Informed Consent Forms  .............................................................................................. 21 
11.3  Participant Confidentiality  ............................................................................................ 21 
11.4  Study Discontinuation  ................................................................................................... 21 
12 ETHICAL CONSIDERATIONS  ....................................................................................... 21 
13 COMMITTEES ................................................................................................................... 22 
14 PUBLICATION OF RESEARCH FINDINGS  ................................................................ 22 
15 REFERENCES  .................................................................................................................... 22 
16 SUPPLEMENTS/APPENDICES  ...................................................................................... 24 
 
   
Protocol Template, Version 3.0 vii PR√âCIS  
Study Title  
Improving How People Living with Dementia Are Selected for Care Coordination:  
A Pragmatic Clinical Trial Embedded in an Accountable Care Organization  
Objectives  
The primary objective is to determine the comparative effectiveness of two different approaches for allocating care coordinators to people living with dementia (PLWD) in the context of a Medicare Accountable Care Organization (ACO) (i.e., based on care partner s‚Äô reported need for care coordination vs. usual care, which is typically after 
hospital discharge) on the combined outcome of emergency department (ED) visit or hospital admission over 12 months of follow- up, as measured in claims.  
 The secondary objective is to measure implementation outcomes for the trial to inform future dissemination: acceptability (percent of participants who engage with the care coordinators), appropriateness (types and frequencies of different care coordination services provided), fidelity (percent of eligible individuals who receive care coordination services based on perceived need), and efficiency (total number of care coordinator hours), as measured with data from electronic health records.  
Design and Outcomes   
The proposed study is a pragmatic clinical trial embedded in a Medicare ACO with prospective randomization to determine the comparative effectiveness of two different approaches for allocating care coordinators to PLWD. It will include Medicare beneficiaries who have had fragmented ambulatory care (that is, care spread across multiple providers without a dominant provider), because individuals with fragmented ambulatory care are at risk for gaps in communication across providers, which care coordinators can address.   Figure 1. Overview of study design 
 
 
 
 
 
    
 
Participants will be followed for the primary combined outcome of emergency department visit or hospitalization over 12 months. 
Community -dwelling Medicare beneficiaries ‚â•65 years old with 
dementia who are attributed to the NewYork Quality Care ACO 
and had fragmented ambulatory care in the past 12 months  
Intervention approach for 
assigning care coordinators  
Usual approach for assigning 
care coordinators  
Protocol Template, Version 3.0 viii Interventions and Duration  
Overview:   This study will leverage the existing infrastructure of the NewYork Quality 
Care (NYQC) ACO, which already works with care coordinators. Care coordinators are 
members of the medical team (typically with previous training in nursing, social work, or another related field) whose job it is to facilitate communication among all the participants involved in an individual‚Äôs care. ACOs typically have thousands of patients assigned, or attributed, to them by Medicare and only a few care coordinators. Thus, care coordinators are a scarce resource, and it is not known how best to allocate them. This study will not change what care coordinators do; rather, it will test the comparative 
effectiveness of two different strategies for allocating care coordinators to PLWD.  
 
Usual care:   Usual care assigns attributed patients to care coordinators in response to: 1) a 
discharge from an NYQC hospital (approximately 80% of cases), 2) a discharge from a non-NYQC hospital (approximately 15% of cases), or 3) a referral from an NYQC physician asking for care coordi nation for a specific patient (approximately 5% of cases).   
 
Intervention:  The intervention group will assign care coordinators to PLWD based on 
perceived need for assistance with care coordination, as follows. The PLWD who are randomized to the intervention arm will each receive an initial call from a care coordinator, which we will refer to as the ‚Äúscreening‚Äù call. If the patient has severe dementia and is not able to participate in a phone call (as judged by the care coordinator), the care coordinator will reach out to the healthcare proxy documented in the EHR. T he 
care coordinator will administer a previously validated 7-minute telephone survey on 
perceptions of care coordination. If the patient or proxy responds to the survey in a way that indicates a perceived problem with care coordination in the past 6 months (i.e., a ‚Äúpositive‚Äù response to ‚â•1 of 8 questions, as defined previously), t hen we will consider 
this a ‚Äúpositive screening.‚Äù The care coordinator will then ask open-ended questions to understand the specific problem with care coordination and proceed to address it. (As in the usual care group, referrals from NYQC physicians asking for care coordination for a specific patient will also be allowed for the intervention group.) 
 
Timeline:  The first 3 months after randomization will be considered the period of time 
for qualifying events (e.g. a hospitalization in the usual care group or a positive survey in the intervention group). PLWD who are assigned to care coordinators (in both groups ) 
will receive care coordination services for a minimum of 30 days. After 30 days, the 12-month follow-up period (for the occurrence of and ED visit or hospitalization) will begin.  
Sample Size and Population  
We will include Medicare beneficiaries ‚â•65 years old who: 1) are attributed to NYQC by Medicare, 2) have dementia (using the previously validated Bynum-Standard 1- year 
definition for ICD-10 codes), 3) reside in the community, and 4) had fragmented ambulatory care in the previous 12 months (defined as a reversed Bice- Boxerman Index 
‚â•50
th percentile) . At the time of the grant application, 688 individuals met these criteria. 
We will recalculate eligibility at the start of the trial, since attribution changes over time, but we expect the total number of eligible individuals to be similar.
Protocol Template, Version 3.0 1  
STUDY TEAM ROSTER  
List individuals who play key roles in the development and execution of the study, especially 
those who may need to be contacted by the sites during the course of the study.  Include address, telephone, fax and e-mail address of each individual listed and include a brief summary of each individual‚Äôs main responsibilities.  
Principal Investigator: Name :  Lisa M. Kern, MD, MPH 
Weill Cornell Medicine  
420 East 70
th Street, Room LH-349 
New York, NY 10021 
T: 646-962-5889 E: lmk2003@med.cornell.edu
 
Role:  PI  (As PI, Dr. Kern will oversee all aspects of the 
research, including coordination of the research team (including the subcontract to NewYork Quality Care), study design, data collection, data analysis, interpretation of results, manuscript preparation, diss emination of results , and 
coordination with the IMPACT Collaboratory.)  
Co-Investigators:  Name : Samprit Banerjee, PhD  
Weill Cornell Medicine  
402 East 67
th Street, Room LA-233 
New York, NY 10065 T: 646-962-8014 E: sab2028@med.cornell.edu
 
Role:  Biostatistician  (As the Biostatistician, Dr. Banerjee 
will contribute his methodological expertise to this project, advising on study design, overseeing randomization, and overseeing statistical analysis. He will also assist with revising manuscripts for critical scientific content. ) 
 Veerawat Phongtankuel, MD Weill Cornell Medicine  
525 East 68
th Street, Payson 2 
New York, NY 10065 T: 212-746-1501 E: vep9012@med.cornell.edu
 
Role:  Geriatrician (Dr. Phongtankuel will contribute to this 
project his expertise in the clinical care of patients with dementia, contributing to study design, interpretation of results, revisions of manuscripts, and dissemination. He will also be available to the PI and the care coordinators as a clinical resource. ) 
Protocol Template, Version 3.0 2  
Catherine Riffin, PhD Weill Cornell Medicine  
420 East 70
th Street, 3rd Floor 
New York, NY 10021 T: 646-962-7160 E: acr2213@med.cornell.edu
 
Role:  Social scientist (Dr. Riffin will contribute her 
expertise in family care partners for individuals with 
dementia, contributing to study design, interpretation of results, revisions of manuscripts, and dissemination.  She 
will be available to the PI and the care coordinators for any questions that may arise with the proxy respondents.) 
 PARTICIPATING STUDY SITES  
 List the name and address of each study site investigator, including telephone numbers and e-mail address. Use the same format as used for the Study Team roster.   
Site PI :           Name :            Paul Casale, MD, MPH  
NewYork Quality Care (NYQC)  
520 East 70
th Street  
New York, NY 10021 T: 646-962-2735 E: pnc9003@med.cornell.edu
 
Role:  Co -I, Executive Director of NYQC (Dr. Casale will 
contribute to this project his expertise on how advancing care coordination aligns with the goals of accountable care organizations. He will contribute to interpretation of study results. Dr. Casale will also oversee the activities of the  
NewYork Quality Care staff .) 
 
Note on the relationship between Weill Cornell Medicine and NewYork Quality Care:  
NewYork Quality Care is an accountable care organization that brings together NewYork-Presbyterian Hospital, Weill Cornell Medicine, and ColumbiaDoctors. Weill Cornell Medicine is thus a part of NewYork Quality Care. NewYork Quality Care does not have its own IRB and instead relies on the IRBs of its component organizations. We are providing a letter from NewYork Quality Care, saying that for this project they cede IRB oversi ght to Weill Cornell 
Medicine and thus cede to the Advarra IRB. 
  
  
Protocol Template, Version 3.0 3 1 STUDY OBJECTIVES  
1.1 Primary Objective  
The primary objective is to determine whether a novel approach to allocating care 
coordinators to PLWD (i.e., based on care partners‚Äô perceived need for care coordination) results in fewer ED visits and hospitalizations over 12 months, compared to usual care, which allocates care coordinators to PLWD after hospital discharge.  
1.2 Secondary Objectives  
The secondary objective is to determine the acceptability (percent of participants who 
engage with the care coordinators), appropriateness (types and frequencies of different care coordination services provided), fidelity (percent of eligible individuals who receive care coordination services based on perceived need), and efficiency (total number of care coordinator hours) of this novel approach to allocating care coordinators to PLWD based on care partners‚Äô perceived need for care coordination. 
2 BACKGROUND AND RATIONALE   
2.1 Background on Condition, Disease, or Other Primary Study Focus 
In response to a survey in 2021 about how their organizations approach care for PLWD, members of the NEJM Catalyst Insights Council (>500 clinicians, clinical leaders, and executives directly involved in care delivery) reported that ‚Äúfragmentation of care delivery‚Äù is the #1 barrier to improving dementia care.
1 Fragment ation of care delivery 
refers to ambulatory  care that is spread across numerous ambulatory providers without a 
dominant provider.2,3 Seeing multiple providers may be clinically appropriate, but it 
increases the risk of gaps in communication across providers caring for the same patient.4 
Fragmented ambulatory care is ubiquitous in the U.S., with  25% percent of Medicare 
beneficiaries ‚â•65 years old see ing ‚â•11 ambulatory providers each year.5-7  Although 
PLWD may not be the only people who experience fragmentation of care, they may be particularly vulnerable to its adverse effects ; that is, they may not have the physiologic 
reserves to withstand the drug-drug interactions, repeat tests, and unnecessary procedures that are associated with fragmented care.
8 How best to address fragmented ambulatory 
care for PLWD is not known. 
Care coordination is one solution to fragmented ambulatory care, and care coordination 
has been found to be an efficacious intervention for PLWD.9 However, there are not 
enough care coordination resources for all the people who might benefit from their help.10 
‚ÄúCare coordinators‚Äù are members of the medical team whose job it is to facilitate communication among all the participants involved in a patient‚Äôs care.
11,12 They  usually 
have previous training in nursing or social work,13,14 and they are already employed by 
providers across the country,  including accountable care organizations (ACOs).11 An 
ACO is a formal organization that brings together physicians, hospitals, and other clinical entities for the purpose of providing care to a population of patients.
15 ACOs contract 
with payers, such as Medicare.15 ACOs typically have thousands of attributed patients 
(including PLWD) and only a small number of care coordinators. For example, an ACO with 9,000 attributed patients may only have 3 care coordinators, who can care for 
Protocol Template, Version 3.0 4 approximately 350 patients each, for a total of 1,050 patients (12%).10 Determining how 
best to allocate care coordinators is critical for patient outcomes and the success of the 
ACO. However, there have been no studies of the comparative effectiveness of different approaches.  
2.2 Study Rationale  
The usual approach for selecting the patients who will receive assistance from care 
coordinators is to select patients who are the ‚Äúsickest‚Äù (based on type or severity of 
illness) or who experience a transition in care, such as a hospital discharge.
16,17 This 
approach is reasonable, but it assumes that all patients meeting those criteria have 
problems with care coordination, which they may not. The usual approach also has the disadvantage of often waiting until after a hospitalization, at which point the pa tient, care 
partner, and care coordinator need to manage not only the illness that prompted the 
hospital admission but also any complications from the admission itself.  
An alternate approach would identify patients and care partners who experience problems 
with care coordination and then assign care coordinators to them. This approach would 
involve identifying patients with highly fragmented care (who are at high risk of having 
poor care coordination) and then asking them or their care partners their perceptions of 
the extent to which care is coordinated. Patients and care partners have a unique vantage point from which to detect gaps in care coordination, as they are the first to know if the patient seeks care from multiple health systems.
18 They are also often the first to know if 
something with care does not seem right, such as being asked to repeat a test.18 In a 
national 2020 survey by AARP, 31% of care partners for PLWD reported difficulty coordinating care among their care recipient‚Äôs providers, which was up from 23% in 
2015.
19 Self-reported concerns with care coordination have recently been validated 
against objective measures of quality of care.20 
This study is based on a conceptual model that has arisen from Dr. Kern‚Äôs previous work 
(Figure 2).4 The model describes the relationships among fragmentation, communication, 
and harm and identifies different time points at which interventions could occur . The 
intervention we are proposing in this application would detect and address gaps in communication before they cause harm (Box F). By contrast, usual care would intervene after a hospital admission (Box G). This is not to say that all hospital admissio ns are 
preventable or related to fragmented care; they are not. However, our preliminary data suggest  that more fragmented care for Medicare beneficiaries over 12 months 
independently increases the risk of an incident ED visit
(under review) or incident hospital 
admission21 in the subsequent 1- 3 months, compared to less fragmented care. The 
magnitude of this association is a 31% increase in the risk of an ED visit (95% confidence interval [CI] 29%, 34%) and, separately, an 18% increase in the risk of a hospital admission (95% CI 12%, 24%). If this risk can be modified with better communication, the potentia l for averted ED visits and hospital admissions is substantial.  
 
 
Protocol Template, Version 3.0 5 Figure 2. Conceptual model describing the relationships among fragmentation, 
communication, and harm 
 
Of note, in a nationwide survey, Black Medicare beneficiaries were significantly more likely than White Medicare beneficiaries to report experiencing an adverse event that they thought could have been prevented with better communication among their healthcare provid ers.
22 Addressing concerns about care coordination has the potential to 
avert preventable events that may disproportionately affect racial minorities.  
3 STUDY DESIGN  
We will conduct a pragmatic clinical trial embedded in an ACO (ePCT) with prospective randomization. The trial consists of a parallel design with two groups of equal size. Masking is not feasible. 
The trial will determine the comparative effectiveness of two different approaches for 
allocating care coordinators to PLWD. The primary outcome is the combined outcome of ED visit or hospitalization over 12 months of follow-up. The secondary outcome consi sts 
of implementation measures (acceptability, appropriateness, fidelity, and efficiency), which will be used to inform future dissemination.  
The setting for the study is the NewYork Quality Care (NYQC) ACO, the ACO that 
brings together NewYork-Presbyterian Hospital, Weill Cornell Medicine, and 
ColumbiaDoctors.
23,24 Individuals in the study have already been assigned to NYQC by 
Medicare and will be contacted by care coordinators who already work with NYQC. 
Interactions between care coordinators and individuals in the study (PLWD or their proxies) will be done by telephone or by video, both of which are part of standard care.  
The study population will consist of Medicare beneficiaries ‚â•65 years old who: 1) are 
attributed to NYQC by Medicare, 2) have dementia (using the previously validated Bynum-Standard 1- year definition for ICD -10 codes),
25,26 3) reside in the community, 
and 4) had fragmented ambulatory care in the previous 12 months (defined as a reversed Bice- Boxerman Index ‚â•50
th percentile) .27,28 At the time of the grant application, 688 
individuals met these criteria. We will recalculate eligibility at the start of the trial, since attribution changes over time, but we expect the total number of eligible individuals to be similar. This population will be randomized to the two arms of the trial (344 per arm).  
At the start of the study, we will have the list of participants and will randomize them into two groups. (We will be requesting a waiver of informed consent and a waiver of HIPAA authorization, as described below in section 4.3, so there will be no recrui tment per se.) 

Protocol Template, Version 3.0 6 The first 3 months after randomization will serve as the period during which individuals 
will have ‚Äúqualifying events‚Äù for receipt of care coordination services. In the usual care group, a qualifying event is discharge from a hospital ization . In the intervention group, a 
qualifying event is a ‚Äúpositive screening call‚Äù (indicating a perceived problem with care coordination) , as described in Section 5.2 below. Direct referrals from physicians to care 
coordinators for assistance with particular patients will b e allowed in both groups. 
Individuals with qualifying events in both groups will receive care coordination services, which will be consistent with the professional standards of the American Case Management Association and the Case Management Society of America.
29,30 Usual care 
includes describing care coordination to the patient or proxy and inviting them to engage in care coordination; approximately 70-80% of people agree to engage. Each interaction with a patient or proxy (including declining care coordination) is documented in the electronic health record (EHR) . Usual care coordination is broad and encompasses post-
discharge medication reconciliation, inquiries about any symptoms post- discharge, a 
review of upcoming appointments, assistance with obtaining transportation, review of paid home care services, and an y other needs that may arise, with the primary goal of 
preventing rehospitalization. Patients and proxies are given the care coordinator‚Äôs contact information and are invited to reach out with any questions or concerns. Care coordination in the intervention group will start narrowly, with the care coordinator seeking to understand the positive screening result (exactly what the patient or proxy thinks is not working well and why). The care coordinator will then seek to address the issue, documenting the proce ss in the EHR. The care coordinators will be free to engage 
in broader care coordination activities (e.g., general medication reconciliation, reviewing upcoming appointments, arranging transportation, etc.) at their discretion. 
The length and frequency of interactions between the patient or proxy and the care 
coordinator varies depending on the patient‚Äôs needs and the care coordinator‚Äôs discretion. Patients are followed for a minimum of 30 days and a maximum of 1 year, which is a typical duration for care coordination.
31 Care coordination starts at the time of the 
qualifying event. Follow-up for ED visits and hospitalizations begins after the first 30 days of care coordination.   
4 SELECTION AND ENROLLMENT OF PARTICIPANTS   
Key components of the success of a clinical study are the selection and enrollment of participants who are reasonably representative of the populations or characteristics under investigation to allow for sufficient generalizability.  This section should define and describe the study population. 
4.1 Inclusion  Criteria  
Participants must meet all of the inclusion criteria to participate in this study.  
‚Ä¢ Medicare beneficiaries ‚â•65 years old who are attributed to NYQC by Medicare ,
24  
‚Ä¢ Who have dementia, using the previously validated Bynum-Standard 1- year 
definition with ICD -10 codes  from Medicare claims for the previous 12 months ,25,26 
and 
Protocol Template, Version 3.0 7 ‚Ä¢ Who had fragmented ambulatory care, based on Medicare claims  in the previous 12 
months , defined as a reversed Bice- Boxerman Index (BBI) score ‚â•50th percentile . 
27,28 
ùëüùëüùëüùëüùëüùëüùëüùëüùëüùëüùëüùëüùëüùëüùëüùëü  ùêµùêµùêµùêµùêµùêµ = 1‚àíùêµùêµùêµùêµùêµùêµ = 1‚àí ÔøΩ‚àëùëõùëõùëñùëñ2ùëùùëù
ùëñùëñ=1ÔøΩ‚àíùëõùëõ
ùëõùëõ (ùëõùëõ‚àí 1) 
where  n = total number of ambulatory visits in the 12- month period  
 n i = number of ambulatory visits to provider i 
 p = total number of ambulatory providers 
4.2 Exclusion Criteria  
All candidates meeting any of the exclusion criteria at baseline will be excluded from 
study participation. 
‚Ä¢ Those whose addresses are the same as the addresses of nursing homes and other long- term care facilities, as those individuals have distinct care coordination 
needs.  This is routinely captured by the NYQC ACO. 
‚Ä¢ Those who are enrolled in home hospice, as captured in Medicare claims. The 
rationale for excluding these individuals is that they are not at the same risk of 
having an ED visit or hospitalization as other community-dwelling individuals. By virtue of being enrolled in home hospice, they have essentially agreed not to receive services in those more acute settings.  
4.3 Study Enrollment Procedures  
For this trial, we are collaborating with the NYQC ACO. The Centers for Medicare & Medicaid Services (CMS) requires that ACOs inform Medicare beneficiaries if their doctor chooses to participate in an ACO.
32 This notification can come in the form of a 
letter, written information provided when the patient sees the doctor, a sign posted in the doctor‚Äôs office, or a verbal conversation between patient and doctor.
32 NYQC chooses to 
notify patients by putting up posters in their providers‚Äô practices. Medicare be neficiaries 
do not have to seek care within the ACO; they are free to seek care elsewhere.  NYQC 
receives from CMS the names of the patients that have been assigned, or attributed, to NYQC. Attribution is done by CMS and is based on prior healthcare utilization. 
We are requesting a waiver of informed consent.  We believe that the study meets the 5 
Common Rule criteria for a waiver,33 as follows. 
 (i) Minimal risk: The research involves no more than minimal risk to the subjects, because receipt of care coordination services is part of standard clinical care. 
Completing the survey is also minimal risk, as the survey does not inquire about sensitive topics. Review of data in the electronic health record and analysis of claims data are also minimal risk activities.  
 
(ii) Practicability: The research could not practicably be carried out without the waiver. This is because, during usual care, patients are not aware of care coordinator resources unless they are assigned a care coordinator through a physician referral or after  a recent discharge. If we were to try to obtain informed 
Protocol Template, Version 3.0 8 consent, we would need to explain care coordination, which may then raise 
concerns about care coordination among the participants and proxies. This would be especially problematic in the control group, which by the design of the study cannot directly reque st the assistance of care coordinators. This would then create 
problems for the feasibility and validity of the trial.  
 (iii) Identifiable information: The research could not practicably be carried out without the use of identifiable information. The trial relies on identifying community-dwelling Medicare beneficiaries 65 years and older with dementia who are attributed to NewYork Quality Care. We then need to reach out to those individuals who qualify for care coordination in each group, provide care coordination services, review their electronic health record data for implementation outcomes, and follow them over time for the oc currence of 
emergency department visits and hospital admissions as captured in claims. This study is not possible without the use of identifiers.  
 (iv) Rights and welfare: The waiver will not adversely affect the participants‚Äô rights. There is uncertainty about the optimal way to allocate care coordinators; this study is a comparative effectiveness trial of two approaches. Which approach is superior is currently unknown. In addition, even if a waiver is granted, eligible participants in both groups will have the option to agree to or decline care coordination services. 
 (v) Distribution of pertinent information after the trial: NYQC will have the opportunity to distribute the results of the trial to its attributed population. This may take the form of posters or flyers distributed in doctors‚Äô offices, a form of communication which NYQC has used previously. 
We are also requesting a full waiver of HIPAA authorization for this study. We are 
requesting this for use of protected health information from the EHR and for use of Medicare claims for research purposes (both recruitment and outcome assessment) in compliance with the HIPAA Privacy Law. We believe that the study meets the criter ia for 
a full HIPAA waiver, as follows: 
(i) Use or disclosure involves no more than minimal risk to the privacy of individuals:  We have an adequate plan in place to protect health information identifiers from improper use or disclosure. We will destroy identifiers at the earliest opportunity, absent a health or research justification or legal requirement to retain them. We also have adequate written assurances that the protected health information will not be used or disclosed to a third party, except as required by law, for authorized oversight of the research study, or for other research uses and disclosures permitted by the Privacy Rule. 
(ii) Research could not practicably be conducted without the waiver: The research could not practicably be carried out without the waiver because, during usual care, patients are not aware of care coordinator resources unless they are assigned a care coordinato r through a physician referral or after a recent discharge. If we 
Protocol Template, Version 3.0 9 were to try to obtain authorization , we would need to explain care coordination, 
which may then raise concerns about care coordination among the participants 
and proxies. This would be especially problematic in the control group, which by the design of the study cannot directly request the assistance of care coordinators. 
This would then create problems for the feasibility and validity of the trial. 
(iii) Research could not practicably be conducted without access to and use of PHI: 
The research could not practicably be carried out without the use of identifiable 
information. The trial relies on identifying community- dwelling Medicare 
beneficiaries 65 years and older with dementia who are attributed to NewYork Quality Care. We then need to reach out to those individuals who qualify for care coordination in each group, provide care coordination services, review their electronic health record data for implement ation outcomes, and follow them over 
time for the occurrence of emergency department visits and hospital admissions as captured in claims. This study is not possible without the use of identifiers. 
If this waiver is granted, then there will be no recruitment or enrollment per se, because we will include 100% of eligible individuals. Even with a waiver of informed consent, participants in both the intervention and control groups will be able to decline care coordination services if they do not want them. Currently, with usual care, about 70- 80% 
of Medicare beneficiaries who are approached by the NYQC care coordinator agree to engage in care coordination. Each interaction with a patient or proxy (including declining 
care coordination) is documented in the EHR.   Of note, under usual care, care coordinators interact with PLWD and informally assess their capacity to participate in answering questions related to their healthcare. If care 
coordinators believe that the PLWD cannot accurately answer questions related to  their 
healthcare, they contact the healthcare proxy listed in the electronic health record. We will apply this approach to the intervention group as well. We considered expanding ‚Äúcare partners‚Äù to non -healthcare -proxies, but since this is not consistent with usual care, 
we will not. Thus, we will not consider proxies to be separate participants in the trial; they will answer questions on behalf of the PLWD. We are not asking any information about the proxies themselves. Care coordinators routinely document in the EHR whether they spoke to the patient or proxy.  
If a patient has severe dementia and does not have a healthcare proxy documented in the EHR, the patient will not be excluded (because they are still the responsibility of the ACO); in that case, the care coordinator will review the EHR to assess the exten t of care 
coordination and rectify any apparent gaps in communication. 
Randomization will be overseen by Dr. Samprit Banerjee (biostatistician). He will advise 
the data analyst at NYQC on how to employ random number generators to randomly allocate the study population into two equal size groups. Masking is not feasible for this study, so NYQC will be aware of which patients are allocated to which group. This is necessary, because they will need to conduct screening surveys for everyone in the intervention group. (See section 5.2 for a more detailed discussion of masking.)  
Protocol Template, Version 3.0 10 5 STUDY INTERVENTIONS   
5.1 Interventions, Administration, and Duration  
The intervention in this trial is the method for allocating PLWD to care coordinators. The 
content of the care coordination services will be essentially the same in both groups, with slight differences in the start of care coordination (whether focused on the problem that led to a positive survey screen or whether focused on post- discharge management). 
Overall, though, care coordination service s will be highly flexible and tailored to meet 
each patient‚Äôs needs, as is standard.  See section 5.2 for more information. 
5.2 Handling of Study Interventions  
As above, the intervention consists of a novel method for assigning care coordinators to PLWD based on perceived need. Perceived need will be measured with a previously validated 7 -minute telephone survey. This survey consists of 22 questions, has been 
previously administered to more than 7,000 adults ‚â•65 years old (with funding from Dr. 
Kern‚Äôs R01 HL135199), and is published.34 This published paper, which includes the 
survey instrument as an appendix, is being provided to the IRB with this protocol. The survey includes 8 questions regarding perceptions of care coordination; the other 
questions relate to self -reported ambulatory utilization and self-reported preventable 
adverse events. The 8 questions on perceptions of care coordination include 6 questions from the previously validated Care Coordination Measure for the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Medicare survey, which was previously tested on more than 300,000 Medicare beneficiaries
35 These 8 questions ask (using 
different  wording) whether the respondent has experienced difficulty with care 
coordination over the past 6 months, and the responses are ultimately combined into a single indicator for the presence or absence of a self -reported problem with or ‚Äúgap‚Äù in 
care coordi nation. Of the 7,568 respondents in the original administration (average age 77 
years), 38% reported a gap in care coordination.
34 
Care coordinators will administer this survey by telephone to participants (patients or proxies) in the intervention group. The care coordinators will document the survey responses in customized data entry form in REDCap, a secure web -based data 
management platform.
36 If the patient or proxy responds to the survey in a way that 
indicates a perceived problem with care coordination in the past 6 months (i.e., a ‚Äúpositive‚Äù response to ‚â•1 of 8 questions, as defined previously),
34 then we will consider 
this a ‚Äúpositive screening.‚Äù Care coordinators will be trained in advance to recognize ‚Äúpositive‚Äù responses and respond to them in real time, asking open ended questions to understand why the respondent felt that that there was a problem with care coordination. For patients and proxies whose screening calls were ‚Äúnegative‚Äù (not revealing a perceived problem with care coordination), the care coordinators will give them their contact information and invite them to reach out with any questions or concerns. NYQC considers administration of this survey to be part of clinical care. 
We will have a data analyst review the survey responses to measure (as part of the 
implementation measure for fidelity)  whether surveys were correctly categorized as 
positive or negative. For the control group, an administrator at NYQC is responsible for querying daily the 
Protocol Template, Version 3.0 11 Epic EHR to identify discharges from NYQC hospitals and for querying daily a New 
York City health information exchange called NYCLIX to identify hospital discharges from non- NYQC hospitals.
 37,38 (An emergency department visit that results in discharge 
to home without hospital admission does not qualify.) The administrator assigns each discharged  patient to a care coordinator, who then reaches out to the patient by phone.  
Care coordination services for both groups will be provided consistent with the professional standards of the American Case Management Association and the Case Management Society of America.
29,30 Most components of care coordination  are flexible 
and can be varied by staff. For example, the care coordinators will have some discretion over what types of care coordination tasks to engage in. Facilitating provider -provider 
communication will be emphasized in the intervention group, but c are coordinators can 
also help with other tasks, such as reviewing upcoming appointments or arranging 
transportation. One of our implementation outcomes will consist of measuring the frequencies of different types of care coordination activities in the two groups. This is a highl y pragmatic approach. 
Masking is not feasible for this study, so NYQC will be aware of which patients are allocated to which group. This is necessary, because the care coordinators will conduct screening surveys for everyone in the intervention group. The care coordinators will know that this is part of a research study. The same care coordinators may be assigned to individuals in the intervention group and in the control group. However, w e do not expect 
contamination to be an issue, because an administrator at NYQC (the same on e who 
monitors hospitalizations) will assign intervention patients to the care coordinators for administration of the survey. The administrator will supervise the care coordinators to ensure that they approach patients as intended (either for post -discharge planning or for 
assessment through the survey).  
Interactions between care coordinators and individuals in the study (PLWD or their proxies) will be done by telephone or by video, both of which are part of standard care. Note that all participants will be included, regardless of language spoken. For non-English speaking patients, the care coordinators use a professional interpreter service, which they conference in through an 800 number. The current service they use is 
LanguageLine Solutions, which provides on- demand, live interpreters in more than 200 
languages  (https://www.langu ageline.com/s/ ). Because this is a usual care process, we are 
not planning to have any translations  reviewed by Advarra . 
Additional considerations:  The research team carefully considered how to handle several complexities that are interrelated. (1) Consistent with standard practice in which patients are followed for a maximum of 1 year, patients in the usual care group may continue to have events that  qualify them for care coordination beyond the 3- month timeframe that 
we have specified for the ‚Äúqualifying event window.‚Äù That is, patients in the usual care group will continue to be assigned care coordinators when they are hospitalized and discharged. (2) Patients randomized to the intervention group may be hospitalized during the first 3 -month qualifying- event -window and after that window as well. (3) Patients 
randomized to the intervention group may be referred by their phys icians for care 
coordination, just as that occurs for about 5% of the usual care participants. To address these complexities, we have developed the following approach. If a physician refers a 
Protocol Template, Version 3.0 12 patient who is assigned to the intervention group to care coordination, we will honor that 
referral and provide care coordination. If a patient in the intervention group has a hospital admission at any time (during the first 3 -month qualifying window or during follow-up), 
we will administer the perceptions of care coordination survey after discharge and provide care coordination if the survey indicates a need. We believe this is more ethical than not providing care coordination at all to discharged patients in the intervention group; assignment of care coordinators would still be made based on reported problems with care coordination and not given automatically. Thus, during the 3-month window for qualifying events, all participants in the intervention group will receive the survey; after that, the survey will be given to those intervention participants who are discharged from the hospital. 
5.3 Concomitant Interventions 
5.3.1 Allowed Interventions  
Not applicable
 
5.3.2 Required Interventions  
Not applicable 
5.3.3  Prohibited Interventions 
Not applicable  
5.4 Adherence Assessment  
We will measure different versions of adherence when we collect implementation 
outcomes for the secondary objective of the study. These implementation outcomes will be collected by a research assistant, who will review the EHRs for participants in both study groups. The research assistant will extract data from the EHRs manually, using a 
structured form in REDCap. The following implementation outcomes will be collected: acceptability (percent of participants who engage with the care coordinators in both groups), appropriateness (types and frequencies of different care coordination services 
provided in both groups), fidelity (percent of eligible individuals who receive care coordination services based on perceived need in the intervention group), and efficien cy 
(total number of care coordinator hours in both groups ). These implementation outcomes 
are drawn from the Consolidated Framework of Implementation Research (CFIR) and related work by Proctor et al.
39-41 
6 STUDY PROCEDURES  
6.1 Schedule of Evaluations 
This trial does not have a schedule of evaluations per se. Instead, we show a timeline of 
events for all participants in the trial (Figure 3). 
  
Protocol Template, Version 3.0 13 Figure 3. Timeline of events for each participant (not to scale) 
 
 
 
   
*See section 3 for the definition of qualifying event, which varies based on the arm of the trial  
‚Ä†Care coordination may extend beyond 30 days for participants in either trial arm, at the 
discretion of the care coordinator, but the follow -up period still starts after the initial 30 days of 
care coordination. For those participants who do not have a qualifying event, their follow-up period for ED visits or hospitalizations will start 4 months after randomizat ion (simulating the 
3-month qualifying period + 1 month during which they did not receive care coordination). See also section 5.1 for more information.  
 
The study will use three data sources: the survey on perceptions of care coordination, 
the EHR, and Medicare claims. The survey data will be used to determine eligibility for 
care coordination in the intervention group. The EHR will be used to collect demographic and clinical characteristics of patients (age, race, sex, co -morbidities), as 
well as the implementation outcomes. Medicare claims will be used to measure fragmentation as an eligibility criterion and the primary outcome of ED visit or hospital admission over 12 months. The survey will be administered by care coordinators, the 
EHR data collection will be done by a research assistant, and the Medicare claims will be analyzed by data analysts.  Note that all participants will contribute data to the study whether they are selected for care coordination or not. This is because we are comparing two methods for allocating care coordinators, and we are interested in ED and hospitalization outcomes for both those selected and those not selected.   
 6.2.   Description of Evaluations  
6.2.1 Screening Evaluation  
Consenting Procedure 
We are requesting a waiver of informed consent and a waiver of HIPAA authorization (see section 4.3). 
Screening   
This is not applicable, because the study will include all community -dwelling 
Medicare beneficiaries with dementia who have been attributed to NYQC and had 
Randomization  
Qualifying event window (first 3 months)  
Selected for 
coordination if 
and when a 
qualifying event 
occurs*  
Initial 30 days of 
care coordination (starting with date of qualifying event, which may vary 
across participants)  
Follow -up over 12 months for 
the combined outcome of ED visit or hospitalization, as 
measured in claims‚Ä†  
Protocol Template, Version 3.0 14 fragmented care in the past 12 months. All of these criteria will be measured using 
claims, not interactions with patients or proxies.  
6.2.2 Enrollment, Baseline, and/or Randomization 
Enrollment 
The enrollment date for all participants will be the date of randomization.  
Baseline Assessments  
The research assistant will manually review the EHR for participants‚Äô demographic characteristics (age, race, sex, co -morbidities).  
Randomization 
See section 6.1 for a timeline of randomization, intervention, and follow-up. 
6.2.3 Follow- up Visits  
Follow- up visits per se are not applicable to this trial. The length and frequency of 
interactions between the care coordinator and patient or proxy will vary with the patient‚Äôs needs and care coordinator‚Äôs discretion. 
6.2.4 Completion/ Final Evaluation  
A completion or final evaluation visit is not applicable to this trial. The length and frequency of interactions between the care coordinator and patient or proxy will vary 
with the patient‚Äôs needs and care coordinator‚Äôs discretion. The ED and hospitalization outcomes will be measured in claims.  
7 SAFETY ASSESSMENTS  
7.1 Specification of Safety Parameters  
This is not a drug trial, so we will not be assessing safety with laboratory values. See below for how we will monitor safety in this trial.  
7.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters 
This is not a drug trial, so we will not be assessing safety with laboratory values. See below for how we will monitor safety in this trial.  
7.3 Adverse Events and Serious Adverse Events  
Adverse Event (AE):  Any untoward or unfavorable medical occurrence in a clinical 
research study participant, temporally associated with the participants‚Äô involvement in the research, whether or not considered related to participation in the research. 
AEs for this study : AEs may include a mild increase in anxiety or stress on the 
part of the patient or patient‚Äôs healthcare proxy. This may be expected from a discussion about the challenges of navigating healthcare, but is expected to be short-lived, due to the provision of resources to address the problem.  
Serious Adverse Event (SAE):  Any adverse event that: 
‚Ä¢ Results in death  
Protocol Template, Version 3.0 15 ‚Ä¢ Is life threatening, or places the participant at immediate risk of death from the event 
as it occurred  
‚Ä¢ Causes persistent or significant disability or incapacity  
‚Ä¢ Is another condition which investigators judge to represent significant hazards 
SAEs for this study:  Because the study population consists of PLWD, the 
possibility of emergency department visits and hospitalizations may be reasonably 
expected. The occurrence of these events will be measured by the study as outcomes, and it is hypothesized that the intervention group will have fewer of these events than the control group. Because the study population consists of PLWD, the possibility of death is also an expected occurrence, though it is not expected to be related to the intervention. We will monitor for this event as well, although it is not a study outcome per se.  
7.3.1 Reporting Procedures 
Process for identifying AEs  and SAEs:  
If the care coordinators perceive that a patient or healthcare proxy has increased anxiety, 
the care coordinator will report this to the PI, who will consult with the research team‚Äôs geriatrician.  The geriatrician  can discuss the case with the care coordinator and also with 
the patient‚Äôs physicians. 
The research team will analyze Medicare claims monthly to monitor for the outcomes of 
emergency department visits and hospitalizations. These are expected events that will be tracked and reported to the PI. 
Any deaths that are detected through review of electronic health records by the care 
coordinators or research assistant will be reported to the PI. 
Any unanticipated problems encountered by team members will be reported to the PI. 
Severity of Event  
All AEs will be assessed for severity by the PI  using the following scale:  
‚Ä¢ Mild ‚Äì Events require minimal or no treatment and do not interfere with the 
participant‚Äôs daily activities.  
‚Ä¢ Moderate ‚Äì Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning. ‚Ä¢ Severe ‚Äì Events interrupt a participant‚Äôs usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually potentially life-
threatening or incapacitating.  Of note, the term ‚Äúsevere‚Äù does not necessarily equate to ‚Äúserious .‚Äù  
Relationship To Study Intervention  
All adverse events (AEs) will have their relationship to study intervention assessed by the PI who will evaluate the situation  based on temporal relationship and his/her clinical 
judgment. The degree of certainty about causality will be graded using the categories below. In a clinical trial, the study product must always be suspect.  
Protocol Template, Version 3.0 16 ‚Ä¢ Definitely Related ‚Äì There is clear evidence to suggest a causal relationship, and 
other possible contributing factors can be ruled out. The clinical event occurs in a 
plausible time relationship to study intervention administration and cannot be explained by other factors.  
‚Ä¢ Possibly Related ‚Äì There is some evidence to suggest a causal relationship. 
However, other factors may have contributed to the event (e.g., the participant‚Äôs clinical 
condition, other concomitant events). Although an AE may rate only as ‚Äúpossibly related‚Äù soon after discovery, it can be flagged as requiring more information and later be upgraded to ‚Äúprobably related‚Äù or ‚Äúdefinitely related,‚Äù as appropriate.  
‚Ä¢ Not Related ‚Äì The AE is completely independent of study intervention 
administration, and/or evidence exists that the event is definitely related to another etiology. There must be an alternative, definitive etiology documented by a qualified medical profes sional. 
7.3.2 Follow-up for Adverse Events 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to 
the attention of study personnel during interactions between care coordinators and study participants and their proxies. The occurrence of an AE or SAE may also come to the attention of study personnel upon review of medical records. 
All AEs will be captured on the appropriate case report form (CRF). Information to be 
collected includes event description, time of onset, qualified medical professional‚Äôs 
assessment of severity, relationship to study, and time of resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed  to adequate resolution. 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed.  
Reporting schedule:   
 
‚Ä¢ All adverse events  that are serious  (SAE) and unexpected (i.e., have not been 
previously reported for the study‚Äôs intervention) will be reported to the IMPACT 
Collaboratory Regulatory and Data Team  and  NIA IMPACT Collaboratory PO 
for dissemination to the IMPACT Collaboratory DSMB Chair (or the project‚Äôs Safety Officer) within 48 hours of the study‚Äôs knowledge of SAE.  
 
o Only those adverse events that are serious (SAE), unexpected, and related to the intervention  must also be reported to Advarra IRB.  Unexpected 
and unrelated  SAEs will be reported to Advarra IRB on a case-by- case 
basis if requested by the IMPACT Collaboratory DSMB Chair (or the project‚Äôs Safety Officer) or NIA IMPACT Collaboratory PO.  
 
‚Ä¢ All unexpected deaths will be reported to IMPACT Collaboratory Regulatory and 
Data Team  and NIA IMPACT Collaboratory PO for dissemination to  the 
IMPACT Collaboratory DSMB Chair (or the project‚Äôs Safety Officer) 
within 24 
hours of study‚Äôs knowledge of death.  
Protocol Template, Version 3.0 17  
o Advarra IRB does not require the specific reporting of death outside of the 
SAE reporting requirement above, but they will be notified on a case-by-case basis if requested by the IMPACT Collaboratory Chair (or the project‚Äôs Safety Officer) or NIA IMPACT Collaboratory PO.  
 
‚Ä¢ All unanticipated problems  (UPs)  will be reported to the IMPACT 
Collaboratory Regulatory and Data Team and  NIA IMPACT Collaboratory PO 
for dissemination to the Advarra IRB and the IMPACT Collaboratory DSMB Chair (or the project‚Äôs Safety Officer) within 48 hours of the study‚Äôs knowledge 
of the event.  
‚Ä¢ The summaries of all previously reported unexpected and related SAEs, deaths, and UPs, as well as  all other SAEs and AEs will be reported to IMPACT 
Collaboratory Regulatory and Data Team  for dissemination to  Advarra IRB, NIA 
IMPACT Collaboratory PO, and the IMPACT Collaboratory DSMB Chair (or the project‚Äôs Safety Officer) 6 months after the start of enrollment and at the end of 
enrollment or data collection (whichever comes later) , or at a frequency requested 
by the IMPACT Collaboratory DSMB Chair (or the project‚Äôs Safety Officer) or NIA IMPACT Collaboratory PO. 
7.4 Safety Monitoring 
The NIA Guidelines on Data and Safety Monitoring generally require that a NIA-appointed Data and Safety Monitoring Board or Safety Officer monitor clinical trials. This trial will have oversight from the Data and Safety Monitoring Board appointed by the NIA IMPACT Collaboratory. 
8 INTERVENTION DISCONTINUATION  
No interim analysis is planned, as the planned trial is fairly short, with 12 months of follow-up for the combined outcome of an emergency department visit or hospital admission. Interim analyses of emergency department visits and hospital admissions will not likely be sufficiently powered to be meaningful. 
However, findings that might trigger a safety review are the number of unexpected deaths 
in the trial. Such findings are presented to the study statistician or to the Data and Safety Monitoring Board (DSMB) statistician to review the events by group to determine whether there are statistical as well as clinical concerns. The statistician reports his findings to a closed session of the DSMB or to the Safety Officer and/or NIA. The findings are used to determine what steps will be taken.  
9 STATISTICAL CONSIDERATIONS   
9.1 General Design Issues  
The trial is based on the hypothesis that assigning care coordinators to PLWD whose care partners‚Äô perceive a problem with care coordination will result in fewer ED visits and hospitalizations than assigning care coordinators to PLWD at the time of hospita l 
Protocol Template, Version 3.0 18 discharge. To avoid circularity, we will separate exposures and outcomes in time. That is, 
we will have a 3 -month exposure period, during which a hospitalization that prompts care 
coordination will only be counted for the exposure and not as an outcome.  
 The 3 -month time period was chosen, based on preliminary data suggest ing that more 
fragmented care over 12 months independently increases the risk of an incident ED 
visit
(under review) or incident hospital admission21 in the subsequent 1- 3 months, compared 
to less fragmented care.  
 
A parallel design was chosen because it is a robust design that allows for concurrent 
comparisons. The outcome of ED visit or hospitalization will be measured using 
Medicare claims data, which are the gold standard, because they capture events across 
healt h systems and are thus broader than EHRs. 
9.2 Sample Size and Randomization  
The primary outcome is the number of events (emergency department visits or 
hospitalizations) / person- time alive. P reliminary data (for the control group) show an 
average event rate per person of 1.99 events over 334 live days (0.92 years). Using Poisson regression, with a sample size of 688 PLWD and assuming 20% attrition and Œ± = 0.05, we have >90% power to find an ev ent rate ratio of 0.74 (i.e., a reduced event rate of 
1.47 or lower in the intervention group vs. 1.99 in the control group), which is a meaningful difference. Data will be analyzed using an intention- to-treat approach. We 
will use descriptive statistics to report our secondary implementation outcomes; these are designed to inform future iterations and dissemination of this intervention, rather than test hypotheses per se.  
9.2.1 Treatment Assignment Procedures  
Randomization will be overseen by Dr. Samprit Banerjee (biostatistician). He will work with the data analyst at NYQC to enumerate the study population and 
conduct stratified randomization  by care management team . That is, the study 
population will first be stratified into groups based on care management team . 
Within each group the study population will be randomized to the two trial arms, 
so that the trial arms will be of equal size. One rationale for randomizing by care 
management team is that the demograp hic characteristics of patients vary with 
care management team (for example, dual eligible beneficiaries are currently more likely to be assigned to one care management team than another). A second 
rationale for randomizing by care management team is that the clinical styles of 
care management teams may vary. By stratifying randomization by care management team, we will minimize any unmeasured confounding that variation 
by care management team might have otherwise introduced. Randomization will 
be done with random number generators.  
Masking is not feasible for this study, so NYQC will be aware of which patients are allocated to which group. This is necessary, because they will need to conduct screening surveys for everyone in the intervention group. 
Protocol Template, Version 3.0 19 9.3 Interim analyses and Stopping Rules  
No interim analysis is planned, as the planned trial is fairly short, with 12 months of 
follow-up for the combined outcome of an emergency department visit or hospital admission. Interim analyses of emergency department visits and hospital admissions will not likely be sufficiently powered to be meaningful. 
However, findings that might trigger a safety review are the number of unexpected deaths 
in the trial. Such findings are presented to the study statistician or to the Data and Safety Monitoring Board (DSMB) statistician to review the events by group to determine whether there are statistical as well as clinical concerns. The statistician reports his findings to a closed session of the DSMB or to the Safety Officer and/or NIA. The findings are used to determine what steps will be taken.  
9.4 Outcomes  
9.4.1 Primary outcome   
We will measure the occurrence of ED visits and hospital admissions using Medicare claims.  
 
9.4.2 Secondary outcomes   
Secondary outcomes will consist of four implementation outcomes drawn from the Consolidated Framework of Implementation Research (CFIR) and related work by Proctor et al.
39-41 Acceptability  will be operationalized as the percent of study participants 
who are retained in each group over time (that is, continue to engage with the care coordinators when contacted). Appropriateness will be operationalized as: a) the types of 
problems with care coordination uncovered in response to the survey in the intervention group, and b) the frequency of different types of care coordinator activities in each group (i.e., facilitating provider-provider communication, facilitating transportation, etc.). Fidelity  will be measured by tracking the percent of eligible individuals who receive care 
coordination services. Implementation Cost (or Efficiency) will be measured as the total 
number of care coordinator hours spent in each group. Implementation outcomes will be measured through manual review of the EHR, using a structured abstraction tool.  
 
9.5  Data Analyses 
We will compare the characteristics of the PLWD in each study group, using chi-squared tests for dichotomous variables and t-tests for continuous variables, to confirm that the study groups are balanced (p > 0.05).
 We will use Poisson regression to compare study 
groups for the outcome of the number of events (ED visits or hospital admissions) per person- time alive , adjusting for care management team  (as it was used to stratify 
randomization
42) and any co-variates that were imbalanced between the study groups at 
baseline. We will conduct analyses using an intention- to-treat approach, considering all 
individuals as members of the group to which they were randomized. We will use 
descriptive statistics to report implementation outcomes.  
 
Protocol Template, Version 3.0 20 We will take biological sex and race/ethnicity into consideration in both the design and 
valid analysis of the trial. W e will employ inclusive eligibility criteria, including 
individuals in the study regardless of sex or race/ethnicity. We will allocate study participants of both sexes and all races/ethnicities to the intervention and control groups by the unbiased process of randomization. We will conduct unbiased assessment of the occurrence of outcomes in all study participants. We will also use unbiased methods of statistical analysis and inference for the study population overall. In addition, we will conduct analyses to determine if the effect of the intervention varies with subgroups by sex and, separately, by race/ethnicity. For Aim 1 (which has the combined outcome of emergency department visits or hospital admissions), we will conduct exploratory moderator analyses with sex and race as potential moderators of treatment effect by introducing moderator x treatment interactions into our regression models. For Aim 2 (which captures implementation outcomes), we will conduct e xploratory analyses 
stratifying implementation  outcomes (such as the types and frequencies of care 
coordination activities provided) by sex and, separately by race/ethnicity. 
 
10 DATA COLLECTION AND QUALITY ASSURANCE  
10.1 Data Collection Forms 
Care coordinators will collect survey responses, which will be entered into a REDCap form. The research assistant will extract data from the EHR, regarding participant demographics and clinical characteristics, as well as the data for the implementation outcomes. The PI will use separate forms to report data on any AEs and SAEs. 
10.2 Data Management  
A data analyst at Weill Cornell Medicine will be responsible for data management and analysis of the survey data on perceptions of care coordination. A data analyst at NYQC will be responsible for data management and data analysis of Medicare claims.  
10.3 Quality Assurance  
10.3.1 Training 
The PI will coordinate the activities of the members of the research team. The PI will provide any training needed for this study, though the team members are already experienced in the roles they will play. 
10.3.2 Quality Control Committee  
Not applicable 
10.3.3 Metrics  
Not applicable 
Protocol Template, Version 3.0 21 10.3.4 Protocol Deviations 
The PI will meet weekly with the care coordinators, research assistant, and 
geriatrician to follow the progress of the study. The PI will be responsible for detecting and reporting any protocol deviations.  
10.3.5 Monitoring 
See 10.3.4. above. 
11 PARTICIPANT RIGHTS AND CONFIDENTIALITY  
11.1 Institutional Review Board (IRB) Review 
This protocol and any subsequent modifications will be reviewed and approved by the IRB or ethics committee responsible for oversight of the study.  
11.2 Informed Consent Forms  
We are requesting a waiver of informed consent and a waiver of HIPAA authorization, as 
described in section 4.3. 
11.3 Participant Confidentiality  
To minimize the likelihood of a breach in confidentiality, we will use several methods to 
keep data secure. Care coordinators will enter survey data into customized forms that we will build using Research Data Electronic Capture (REDCap), a secure web -based data 
management platform. REDCap was developed by Vanderbilt University, supported in part by the National Institutes of Health. Weill Cornell Medicine provides its investigators with access to REDCap. All other interactions between care coordinators and study participants will be documented in the Epic electronic health record, which has 
its own security features. Identifiable Medicare claims will be maintained by NewYork Quality Care. Access to study data will be restricted to authorized staff, the IRB, and the Office of Human Research Protections  (OHRP) . No publications or presentations arising 
from this research will include personally identifiable information.  
11.4 Study Discontinuation  
The study may be discontinued at any time by the IRB, the NIA, the OHRP, or other government agencies as part of their duties to ensure that research participants are protected.  
12 ETHICAL CONSIDERATIONS  
This study is guided by the ethical principles of the Belmont Report, which was written 
by the U.S. National Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research. This study is also guided by the Common Rule (U.S. Protection 
of Human Subjects).  
Protocol Template, Version 3.0 22 13 COMMITTEES  
Not applicable 
14 PUBLICATION OF RESEARCH FINDINGS  
Any presentation, abstract, or manuscript will be made available for review by the 
sponsor and the NIA prior to submission. 
15 REFERENCES  
1. Sawyer RJ. The growing challenge of dementia care. NEJM Catalyst Innovations in Care 
Delivery 2021;9. (Accessed May 2, 2022 at https://catalyst.nejm.org/doi/pdf/10.1056/CAT.21.0285.) 
2. Elhauge E, ed. The fragmentation of U.S. health care: Oxford University Press; 2010. 3. Stange KC. The problem of fragmentation and the need for integrative solutions. Ann 
Fam Med 2009;7:100-3. 
4. Kern LM, Safford MM, Slavin MJ, et al. Patients' and providers' views on the causes and 
consequences of healthcare fragmentation. J Gen Intern Med 2019;34:899-907. 
5. Barnett ML, Bitton A, Souza J, Landon BE. Trends in outpatient c are for Medicare 
beneficiaries and i mplications for primary care, 2000 to 2019. Ann Intern Med 2021; 
174(12):1658-1665. 
6. Kaiser Family Foundation. Total number of Medicare beneficiaries , 2020. (Accessed 
May 2, 2022, at https://www.kff.org/medicare/state -indicator/total- medicare-
beneficiaries/ .) 
7. Pham HH, Schrag D, O'Malley AS, Wu B, Bach PB. Care patterns in Medicare and their implications for pay for performance. N Engl J Med 2007;356:1130-9. 
8. Amjad H, Carmichael D, Austin AM, Chang CH, Bynum JP. Continuity of c are and 
health c are utilization in older adults w ith dementia in f ee-for-s ervice Medicare. JAMA 
Intern Med 2016;176:1371-8. 
9. Hughes S, Lepore M, Wiener JM, Gould E, for RTI International. Research on care 
coordination for people with dementia and family caregivers. 2017. (Accessed May 2, 2022, at https://aspe.hhs.gov/basic- report/research -care-coordination-people- dementia -
and-family -caregivers .) 
10. Friedman A, Howard J, Shaw EK, Cohen DJ, Shahidi L, Ferrante JM. Facilitators and 
barriers to care coordination in patient -centered m edical homes (PCMHs) from 
coordinators' perspectives. J Am Board Fam Med 2016;29:90-101. 
11. Evans M. Demand grows for care coordinators. Modern Healthcare 2015. 12. American Academy of Ambulatory Care Nursing. Care coordination & transition 
management certification , 2021. (Accessed May 2, 2022, at 
https://library.aaacn.org/aaacn/conferences/16/view.) 
13. School of Public Health at University at Albany, SUNY. New York Health Careers: 
Patient care coordinators. (Accesssed May 2, 2022, at https://www.healthcareersinfo.net/patient- care-coordinators/.) 
14. Karam M, Chouinard MC, Poitras ME, Couturier Y, Vedel I, Grgurevic N, Hudon C. 
Nursing care coordination for patients with complex needs in primary healthcare: a scoping review. Int J Integr Care 2021;21:16. 
Protocol Template, Version 3.0 23 15. Berwick DM. Making good on ACOs' promise --the final rule for the Medicare shared 
savings program. N Engl J Med 2011;365:1753- 6. 
16. Haas LR, Takahashi PY, Shah ND, et al. Risk -stratification methods for identifying 
patients for care coordination. Am J Manag Care 2013;19:725- 32. 
17. Peikes D, Chen A, Schore J, Brown R. Effects of care coordination on hospitalization, 
quality of care, and health care expenditures among Medicare beneficiaries: 15 
randomized trials. JAMA 2009;301:603- 18. 
18. Gallagher TH, Mazor KM. Taking complaints seriously: using the patient safety lens. 
BMJ Qual Saf 2015;24:352- 5. 
19. AARP. Caregiving in the United States, 2020. (Accessed May 2, 2022, at https://www.aarp.org/ppi/info- 2020/caregiving- in-the-united- states.html.)  
20. Elliott MN, Adams JL, Klein DJ, et al. Patient- reported c are c oordination is a ssociated 
with better performance on clinical c are m easures. J Gen Intern Med 2021;36:3665- 71. 
21. Kern LM, Ringel JB, Rajan M, et al. Ambulatory Care Fragmentation and Subsequent Hospitalization: Evidence From the REGARDS Study. Med Care 2021;59:334- 340. 
22. Pinheiro LC, Reshetnyak E, Safford MM, Kern LM. Racial disparities in preventable adverse events a ttributed to poor c are c oordination r eported in a n ational s tudy of older 
US Adults. Med Care 2021;59:901- 6. 
23. NewYork Quality Care website, 2022. (Accessed May 2, 2022, at https://www.newyorkqualitycare.com/ .) 
24. Casale PN, Gordon J, Stewart MG, Cioffi GA, Alge D, Deland EL. Success in a hospital -
integrated accountable care organization.  NEJM Catalyst, Innovations in Care Delivery,  
July 10, 2019. (Accessed May 2, 2022, at https://catalyst.nejm.org/doi/full/10.1056/CAT.19.0642.)  
25. Grodstein F, Chang CH, Capuano AW, et al. Identification of dementia i n recent 
Medicare c laims data, compared t o rigorous c linical a ssessments. J Gerontol A Biol Sci 
Med Sci 2021. 
26. McCarthy EP, Chang CH, Tilton N, Kabeto MU, Langa KM, Bynum JPW. Validation of claims a lgorithms to i dentify Alzheimer's disease and related d ementias. J Gerontol A 
Biol Sci Med Sci 2021.  
27. Bice TW, Boxerman SB. A quantitative measure of continuity of care. Med Care 1977;15:347- 9. 
28. Liu CW, Einstadter D, Cebul RD. Care fragmentation and emergency department use among complex patients with diabetes. Am J Manag Care 2010;16:413- 20. 
29. Case Management Society of America website, 2021. (Accessed May 2, 2022, at https://cmsa.org/.)  
30. American Case Management Association website, 2021. (Accessed May 2, 2022, at https://www.acmaweb.org/ .) 
31. Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA 2006;295:2148- 57. 
32. Centers for Medicare & Medicaid Services. Accountable care organizations and you: Frequently asked questions for people with Medicare , 2011. (Accessed May 2, 2022, at 
https://downloads.cms.gov/medicare/pdf/11588.pdf .) 
33. NIA IMPACT Collaboratory. Modifications and waivers of informed consent in pragmatic clinical trials , 2020. (Accessed May 2 , 2022, at 
Protocol Template, Version 3.0 24 https://impactcollaboratory.org/wp -
content/uploads/2020/02/NIA_IMPACT_RegEthicsCore_grand-rounds_19- Feb-
2020.pdf.) 
34. Kern LM, Reshetnyak E, Colantonio LD, et al. Association between patients‚Äô self-
reported gaps in care coordination and preventable adverse outcomes:  A cross- sectional 
survey. J Gen Intern Med 2020;35:3517-24. 
35. Hays RD, Martino S, Brown JA, et al. Evaluation of a Care Coordination Measure for the 
Consumer Assessment of Healthcare Providers and Systems (CAHPS) Medicare survey. 
Med Care Res Rev 2014;71:192-202. 
36. Research Electronic Data Capture (REDCap) , 2021. (Accessed May 2, 2022, at 
https://projectredcap.org/.) 
37. Kern LM, Grinspan Z, Shapiro J, Kaushal R. Patients' use of multiple hospitals in a major 
U.S. city:  Implications for population management. Popul Health Manag 2017;  20(2):99-
102. 
38. Shapiro JS, Johnson SA, Angiollilo J, Fleischman W, Onyile A, Kuperman G. Health 
information exchange improves identification of frequent emergency department users. Health Aff (Millwood) 2013;32:2193-8. 
39. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering 
implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci 2009;4:50. 
40. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: 
conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health 2011;38:65-76. 
41. Consolidated Framework for Implementation Research: Implementation Outcomes. 2022. 
(Accessed May 2 , 2022, at https://cfirguide.org/evaluation- design/implementation -
outcomes/.) 
42. Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in 
leading medical journals: review and reanalysis. BMJ 2012;345:e5840. 
16 SUPPLEMENTS/APPENDICES  
Article by Kern et al., describing survey instrument to be used in this study (with survey 
instrument included as an Appendix), same as reference #34 above 
 